← Cocrystal Pharma, Inc. (COCP) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Cocrystal Pharma, Inc. (COCP)
Pharmaceutical Preparations · market cap $23M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Cocrystal Pharma (COCP) is a micro-cap ($13M market cap, ~$0.95/share) antiviral drug developer with 11 employees and three Phase 2 assets: CC-42344 (Influenza A), CDI-31244 (Chronic Hepatitis C), and CDI-988 (Norovirus). The nearest catalyst is estimated Q4 2026 Phase 2 data readout for CDI-988 (Norovirus), rated 7/10 importance. No revenue has been reported, the company burns approximately $5–15M annually in R&D, and cash position and runway are undisclosed.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CC-42344 | Phase 2 | Influenza A |
| CDI-31244 | Phase 2 | Chronic Hepatitis C |
| CDI-988 | Phase 2 | Norovirus |
| SOF/VEL | Phase 2 | Chronic Hepatitis C |
Price & technical context
3-month
+4.3%
6-month
-30.7%
12-month
-17.8%
52-wk range
$0.82–$1.57
vs 50-day MA
-12.8%
vs 200-day MA
-12.2%
Realized vol
70.0%
Max drawdown
-74.8%
Daily closes through 2026-10-26. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for COCP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.